Trexquant Investment LP Raises Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Trexquant Investment LP increased its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 52.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 261,184 shares of the company's stock after buying an additional 90,233 shares during the period. Trexquant Investment LP owned 0.20% of Centessa Pharmaceuticals worth $4,375,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CNTA. Geode Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock worth $959,000 after buying an additional 660 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Centessa Pharmaceuticals by 0.3% in the fourth quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock valued at $38,668,000 after buying an additional 6,000 shares during the period. Wellington Management Group LLP grew its position in Centessa Pharmaceuticals by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company's stock worth $1,928,000 after buying an additional 14,494 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Centessa Pharmaceuticals by 40.1% during the 4th quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company's stock worth $3,189,000 after acquiring an additional 54,482 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after acquiring an additional 5,316 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Centessa Pharmaceuticals Trading Down 3.4 %

Shares of CNTA stock traded down $0.40 during trading hours on Monday, hitting $11.28. 1,447,185 shares of the company were exchanged, compared to its average volume of 572,025. The company has a 50 day simple moving average of $16.07 and a two-hundred day simple moving average of $16.30. The firm has a market cap of $1.50 billion, a P/E ratio of -7.37 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.04. Equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CNTA shares. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Guggenheim reissued a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Morgan Stanley reiterated an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $27.71.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the transaction, the general counsel now directly owns 118,265 shares in the company, valued at approximately $1,808,271.85. This trade represents a 4.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $15.77, for a total transaction of $867,350.00. Following the completion of the sale, the chief executive officer now owns 429,398 shares of the company's stock, valued at approximately $6,771,606.46. The trade was a 11.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 260,168 shares of company stock valued at $4,309,568 over the last ninety days. 11.59% of the stock is owned by company insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.